Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection

Journal of Clinical Hypertension

Volumn 18, Issue 1, 2016, Pages 70-78

  Mizuno, Hiroyuki ^a,b   Hoshide, Satoshi ^a   Fukutomi, Motoki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Fukushima Prefectural Minami Aizu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; AMIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; FUMARIC ACID DERIVATIVE; RENIN; SERUM ALBUMIN;

AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BRACHIAL ANKLE PULSE WAVE VELOCITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONSERVATIVE TREATMENT; DRUG EFFECTS; EPIDEMIOLOGY; JAPAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; JAPAN; MALE; ORGAN SPARING TREATMENTS; PROSPECTIVE STUDIES; RENIN; SERUM ALBUMIN;

EID: 84953378522     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12618     Document Type: Article

References (25)

1. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16:14-26.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
3. Shimamoto K, Ando K, Fujita T, et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension: the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253-390.
4. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202.
5. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension. Atherosclerosis. 2011;216:199-204.
6. Holtkamp FA, De Zeeuw D, De Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011;32:1493-1499.
7. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
8. Blacher J, Safar ME, Guerin AP, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003;63:1852-1860.
9. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
10. Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
11. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
12. McMurray JJ, Pitt B, Latini R, et al; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
13. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
14. Gheorghiade M, Böhm M, Greene SJ, et al; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125-1135.
15. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressure compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783.
16. Clement DL, De Buyzere ML, De Bacquer DA, et al; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-2415.
17. Littlejohn TW 3rd, Jones SW, Zhang J, et al. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Human Hypertens. 2013;27:321-327.
18. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915.
19. Rothwell PM, Howard SC, Dolan E, et al; ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480.
20. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56:765-773.
21. Polónia J, Amado P, Barbosa L, et al. Morning rise, morning surge and daytime variability of blood pressure and cardiovascular target organ damage. A cross-sectional study in 743 subjects. Rev Port Cardiol. 2005;24:65-78.
22. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419-1425.
23. Morishita Y, Yasui T, Numata A, et al. Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension. Int J Nephrol Renovasc Dis. 2012;5:125-133.
24. Suzuki H, Okada K, Abe M, et al. Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. Clin Exp Nephrol. 2013;17:386-395.
25. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406.